Information

Related Research Units

The Manton Center for Orphan Disease Research
Psychiatry Research

Research Overview

Dr. Gonzalez-Heydrich, a clinical and research psychiatrist, focuses his research in broad areas early Schizophrenia and risk for Schizophrenia and technological games to develop emotional strength.

The research in Schizophrenia has joined together a multidisciplinary group of investigators in a discovery cycle whose purpose is to translate basic insights into the pathophysiology of psychosis into treatments.  The cycle starts with the development of screening instruments to identify children at risk for schizophrenia as early as possible. These children are being referred for treatment to the Developmental Neuropsychiatry Clinic (DNP) and offered inclusion in ongoing studies. These studies provide phenotyping to describe their behavioral and psychological symptoms and to characterize biomarkers of risk. Among the biomarkers are MRI measures of inflammation and neurophysiologic measures of early information processing and synaptic plasticity. Techniques for evaluating the effectiveness of new treatments are being developed. These integrate the neurophysiologic biomarkers being studied into cognitive/social emotional training as predictors of progress in the training and as an outcome measure to understand the effects of the training.

The research on technological games to enhance development of emotional strength has developed a number of technologies aimed at letting children and adolescents learn how to better regulate their emotions under cognitive and social challenge. Two clinical trials have been completed of a technology developed in the program, a video game called RAGE-Control, including one randomized control trial. Both clinical trials have shown the RAGE-Control game strongly augments the effects of psychotherapy aimed at developing emotional regulation skills.  

Research Background

Joseph Gonzalez-Heydrich, MD is Director of the Developmental Neuropsychiatry Clinic at Boston Children’s Hospital and an Associate Professor of Psychiatry at the Harvard Medical School. He did his undergraduate and medical school at Johns Hopkins, his residency training at UCLA, Stanford, and Boston Children’s Hospital. He has extensive experience designing and running clinical trials and other scientific studies with children who have psychiatric disorders co-occuring with developmental disorders or epilepsy. He has also assembled collaborations to develop computer applications to help patients and families facing serious psychiatric or medical illnesses. These include a series of computer games and technological toys designed to build emotional strength in patients as well as typically developing children. Most recently, he has brought together a multidisciplinary effort to study childhood psychosis and the developmental antecedents to Schizophrenia at Boston Children’s Hospital.

 

Education

Medical School

Johns Hopkins University School of Medicine
1986 Baltimore MD

Residency

Stanford University
1990 Stanford CA

Residency

Boston Children's Hospital
1995 Boston MA

Publications

  1. Validation of an ICD-Code-Based Case Definition for Psychotic Illness Across Three Health Systems. Schizophr Bull. 2024 11 08; 50(6):1482-1488. View Abstract
  2. Characterization of pain and somatization and its relationship with psychopathology in early onset psychosis. J Psychiatr Res. 2024 Nov; 179:77-82. View Abstract
  3. Challenging Case: New-Onset Hallucinations and Developmental Regression in a Child with Autism Spectrum Disorder. J Dev Behav Pediatr. 2024 May-Jun 01; 45(3):e267-e270. View Abstract
  4. Heterogeneity of clinical symptomatology in pediatric patients at clinical high risk for psychosis. BMC Res Notes. 2024 Mar 26; 17(1):88. View Abstract
  5. Validation of an ICD-code-based case definition for psychotic illness across three health systems. medRxiv. 2024 Feb 29. View Abstract
  6. Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. Genes (Basel). 2023 03 23; 14(4). View Abstract
  7. Burden Experienced by Primary Caregivers of Children With Psychotic Disorders and at Clinical High Risk for Psychosis. J Am Psychiatr Nurses Assoc. 2024 May-Jun; 30(3):518-531. View Abstract
  8. 16p13.11 deletion variants associated with neuropsychiatric disorders cause morphological and synaptic changes in induced pluripotent stem cell-derived neurons. Front Psychiatry. 2022; 13:924956. View Abstract
  9. Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder. Am J Psychiatry. 2022 11 01; 179(11):853-861. View Abstract
  10. Evaluation of a scalable online videogame-based biofeedback program to improve emotion regulation: A descriptive study assessing parent perspectives. Internet Interv. 2022 Apr; 28:100527. View Abstract
  11. Novel CAPN1 missense variants in complex hereditary spastic paraplegia with early-onset psychosis. Ann Clin Transl Neurol. 2022 04; 9(4):570-576. View Abstract
  12. Childhood maltreatment and its role in the development of pain and psychopathology. Lancet Child Adolesc Health. 2022 03; 6(3):195-206. View Abstract
  13. Association of Social Gaming with Well-Being (Escape COVID-19): A Sentiment Analysis. Am J Med. 2022 02; 135(2):254-257. View Abstract
  14. ITSN1: a novel candidate gene involved in autosomal dominant neurodevelopmental disorder spectrum. Eur J Hum Genet. 2022 01; 30(1):111-116. View Abstract
  15. A "Proof of Concept" Randomized Controlled Trial of a Video Game Requiring Emotional Regulation to Augment Anger Control Training. Front Psychiatry. 2021; 12:591906. View Abstract
  16. Early role for a Na+,K+-ATPase (ATP1A3) in brain development. Proc Natl Acad Sci U S A. 2021 06 22; 118(25). View Abstract
  17. Underrepresentation of Phenotypic Variability of 16p13.11 Microduplication Syndrome Assessed With an Online Self-Phenotyping Tool (Phenotypr): Cohort Study. J Med Internet Res. 2021 03 16; 23(3):e21023. View Abstract
  18. RCL1 copy number variants are associated with a range of neuropsychiatric phenotypes. Mol Psychiatry. 2021 05; 26(5):1706-1718. View Abstract
  19. P300 amplitude attenuation in high risk and early onset psychosis youth. Schizophr Res. 2019 08; 210:228-238. View Abstract
  20. Diagnostic Uncertainty in a Complex Young Man: Autism Versus Psychosis. J Dev Behav Pediatr. 2019 01; 40(1):72-74. View Abstract
  21. De novo variant of TRRAP in a patient with very early onset psychosis in the context of non-verbal learning disability and obsessive-compulsive disorder: a case report. BMC Med Genet. 2018 11 13; 19(1):197. View Abstract
  22. Young children with psychotic symptoms and risk for suicidal thoughts and behaviors: a research note. BMC Res Notes. 2018 Aug 10; 11(1):568. View Abstract
  23. Social impairment and social language deficits in children and adolescents with and at risk for psychosis. Schizophr Res. 2019 02; 204:304-310. View Abstract
  24. De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome. Mol Genet Metab Rep. 2018 Sep; 16:23-29. View Abstract
  25. Potentially traumatic events in youth with and at clinical high risk for psychosis. Early Interv Psychiatry. 2019 08; 13(4):805-809. View Abstract
  26. Suicidal behaviors and their relationship with psychotic-like symptoms in children and adolescents at clinical high risk for psychosis. Compr Psychiatry. 2017 10; 78:31-37. View Abstract
  27. Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):850-863. View Abstract
  28. Social cognitive impairment in 22q11 deletion syndrome: A review. Psychiatry Res. 2017 07; 253:99-106. View Abstract
  29. A Developmental Perspective on Social-Cognition Difficulties in Youth at Clinical High Risk for Psychosis. Harv Rev Psychiatry. 2017 Jan/Feb; 25(1):4-14. View Abstract
  30. Suicidal behaviors in children and adolescents with psychotic disorders. Schizophr Res. 2017 01; 179:13-16. View Abstract
  31. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001008. View Abstract
  32. Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reports. Am J Med Genet A. 2016 May; 170A(5):1165-73. View Abstract
  33. N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth. Neural Plast. 2016; 2016:4209831. View Abstract
  34. Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res. 2015 Dec; 169(1-3):340-345. View Abstract
  35. Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker. BMC Med. 2015 Nov 02; 13:276. View Abstract
  36. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1321-8. View Abstract
  37. Epilepsy & behavior: My intellectual home for 15 years! Epilepsy Behav. 2014 Nov; 40:96. View Abstract
  38. Comparing stimulant effects in youth with ADHD symptoms and epilepsy. Epilepsy Behav. 2014 Jul; 36:102-7. View Abstract
  39. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):726-35. View Abstract
  40. "RAGE-Control": A Game to Build Emotional Strength. Games Health J. 2013 Feb; 2(1):53-7. View Abstract
  41. Management of psychotropic medication side effects in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012 Oct; 21(4):713-38. View Abstract
  42. Elevated rates of ADHD in mothers of children with comorbid ADHD and epilepsy. Neuropsychiatry (London). 2012 Oct 01; 2(5):385-391. View Abstract
  43. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012 Sep 19; 4(152):152ra127. View Abstract
  44. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep; 19(3):329-37. View Abstract
  45. Evidence-based treatment approach to autism spectrum disorders. Pediatr Ann. 2011 Nov; 40(11):569-74. View Abstract
  46. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy Behav. 2011 Jan; 20(1):95-102. View Abstract
  47. The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders. Pharmaceuticals (Basel). 2010 Sep 10; 3(9):2986-3004. View Abstract
  48. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci. 2010; 2:26. View Abstract
  49. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010 Jul; 18(3):229-37. View Abstract
  50. Use of a virtual community as a psychosocial support system in pediatric transplantation. Pediatr Transplant. 2010 Mar; 14(2):261-7. View Abstract
  51. Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert Rev Neurother. 2009 Dec; 9(12):1747-54. View Abstract
  52. RAGE Control: Regulate and Gain Emotional Control. Stud Health Technol Inform. 2009; 149:335-43. View Abstract
  53. Linkage analysis of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 05; 147B(8):1387-91. View Abstract
  54. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J Psychiatr Pract. 2008 May; 14(3):160-9. View Abstract
  55. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs. 2008 Jan; 17(1):77-84. View Abstract
  56. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008 Feb; 12(2):217-33. View Abstract
  57. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents. Evid Based Ment Health. 2007 May; 10(2):59. View Abstract
  58. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review. J Child Adolesc Psychopharmacol. 2007 Apr; 17(2):165-74. View Abstract
  59. Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy and attention-deficit hyperactivity disorder. Epilepsy Behav. 2007 May; 10(3):384-8. View Abstract
  60. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008; 22(1):88-97. View Abstract
  61. Pharmacological management of a youth with ADHD and a seizure disorder. J Am Acad Child Adolesc Psychiatry. 2006 Dec; 45(12):1527-32. View Abstract
  62. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract. 2006 Jul; 12(4):214-22. View Abstract
  63. Depression experience journal: a computer-based intervention for families facing childhood depression. J Am Acad Child Adolesc Psychiatry. 2006 Feb; 45(2):158-165. View Abstract
  64. A Comparison of Divalproex and Risperidone in Pediatric Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005. View Abstract
  65. Tolerability of Olanzapine and Ziprasidone in Youths with Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005. View Abstract
  66. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2005. View Abstract
  67. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit Hyperactivity Disorder (ADHD). Presented at the Child Neurology Society meeting. 2005. View Abstract
  68. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the International League Against Epilepsy meeting. 2005. View Abstract
  69. A Comparison of Divalproex and Oxcarbazepine in Aggressive Youth with Bipolar Disorder. Presented at the Society for Biological Psychiatry meeting. 2005. View Abstract
  70. Antiepileptic Drugs (AEDs) in the Treatment of Aggression in Children and Adolescents. Child and Adolescent Psychopharmacology News. 2005; 10(1):6-12. View Abstract
  71. Psychopharmacology. . Behavioral and Developmental Pediatrics, A Handbook for Primary Care, Editors S Parker, B Zuckerman and M Augustyn. 2005; 83-89. View Abstract
  72. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the World Psychiatric Association meeting. 2004. View Abstract
  73. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Neurological Association meeting. 2004. View Abstract
  74. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2004. View Abstract
  75. A Comparison of Divalproex, Gabapentin, and Oxacarbazepine in Aggressive Youth. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2004. View Abstract
  76. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the New Clinical Drug Evaluation Unit (NCDEU). 2004. View Abstract
  77. No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. J Child Adolesc Psychopharmacol. 2004; 14(2):295-310. View Abstract
  78. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003 Oct; 42(10):1227-33. View Abstract
  79. No Seizure Exacerbation from Ziprasidone in Youth with Comorbid Epilepsy and Psychiatric Disorders: A Case Series. Presented at that 16th European College of Neuropsychopharmacology Congress. 2003. View Abstract
  80. Comparison of Divalproex and Gabapentin: Effectiveness in Aggressive Youth. Presented at the 16th European College of Neuropsychopharmacology Congress. 2003. View Abstract
  81. An Open Trial of the Safety and Efficacy of Mirtazepine in Children and Adolescents with Social Phobia. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2003. View Abstract
  82. An Open Trial of the Safety and Efficacy of Mirtazapine in Children and Adolescents with Social Phobia. Presented at the Society for Biological Psychiatry meeting. 2003. View Abstract
  83. Use of a computer-based application in a pediatric hemodialysis unit: a pilot study. J Am Acad Child Adolesc Psychiatry. 2003 Apr; 42(4):493-6. View Abstract
  84. Depression Experience Journal: A computer-based intervention for families facing childhood depression. Available online: http://www.experiencejournal.com/depression. 2003. View Abstract
  85. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex and their combination. Journal of the American Academy of Child & Adolescent Psychiatry. 2003; 42(10):1227-1233. View Abstract
  86. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Institue for Psychiatric Services. 2002. View Abstract
  87. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the International Conference on Child & Adolescent Mental Health. 2002. View Abstract
  88. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Presented at the Meeting of the American Psychiatric Association. 2002. View Abstract
  89. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Society for Biological Psychiatry. 2002. View Abstract
  90. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Annual Boston Society of Neurology and Psychiatry Cobb Assembly. 2002. View Abstract
  91. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 2002. View Abstract
  92. Sertaline Treatment for Young Children: Systematic Review of Medical Records. Journal of Child and Adolescent Psychopharmacology. 2002; 12(4):294-5. View Abstract
  93. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Journal of Adolescent Health. 2002; 30(2):125. View Abstract
  94. Future of technology to augment patient support in hospitals. Stud Health Technol Inform. 2002; 80:231-44. View Abstract
  95. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol. 2002; 12(4):337-45. View Abstract
  96. Corticotropin releasing hormone increases apparent potency of adrenocorticotropic hormone stimulation of cortisol secretion. Med Hypotheses. 2001 Nov; 57(5):544-8. View Abstract
  97. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Meeting of the American College of Neuropsychopharmacology. 2001. View Abstract
  98. 3 Years of a Pediatric Psychopharmacology Electronic Medical Records System. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001. View Abstract
  99. An Open Study of Sustained Release Bupropion in Adults with ADHD and Substance Use Disorders. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001. View Abstract
  100. Illness-related concerns of mothers of children with congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2001 Jul; 40(7):847-54. View Abstract
  101. Risperidone Treatment for Aggressive Preschool Children: Systematic Review of Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001. View Abstract
  102. Nefazodone for Depression in Bipolar and Non-Bipolar Youth: Systematic Review of Electronic Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001. View Abstract
  103. Method and system for displaying icons representing informational items stored in a database. 2001. View Abstract
  104. Method and system for displaying icons representing informational items stored in a database. 2001. View Abstract
  105. Corticotropin releasing hormone increases Apparent Potency of ACTH Stimulation of Cortisol Secretion. Medical Hypothesis. 2001; 57(5):544-548. View Abstract
  106. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. MEDINFO 2001. Proceedings of the 12th World Congress on Medical Informatics. 2001; 10:800-804. View Abstract
  107. Cardiac Experience Journal: A computer-based intervention for families facing pediatric heart disease. Available online: http://www.experiencejournal.com. 2001. View Abstract
  108. Zora: a pilot virtual community in the pediatric dialysis unit. Stud Health Technol Inform. 2001; 84(Pt 1):800-4. View Abstract
  109. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50. View Abstract
  110. Implementation of an electronic medical record system in a pediatric psychopharmacology program. Int J Med Inform. 2000 Jul; 57(2-3):109-16. View Abstract
  111. The experience journal: a computer-based intervention for families facing congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2000 Jun; 39(6):727-34. View Abstract
  112. Olanzapine in the Treatment of Bipolar Disorder in Juveniles. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2000. View Abstract
  113. Bupropion SR for Attention Deficit Hyperactivity Disorder (ADHD)in Adults with Bipolar Disorder (BPD)and ADHD. Presented at the New Clincal Drug Evaluation Unit (NCDEU) meeting. 2000. View Abstract
  114. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. Presented at the Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting. 2000. View Abstract
  115. Epilepsy in children and adolescents. Child Adolesc Psychiatr Clin N Am. 1999 Oct; 8(4):671-94. View Abstract
  116. Using 'off the shelf', computer programs to mine additional insights from published data: diurnal variation in potency of ACTH stimulation of cortisol secretion revealed. Comput Methods Programs Biomed. 1999 Mar; 58(3):227-38. View Abstract
  117. Interactive Storytelling Environments: Coping with Cardiac Illness at Boston's Children's Hospital. Proceedings of CHI'98, Association of Computing CHI'98 Machinery Special Interest Group in Computer-Human Interaction Conference. 1998; 603-609. View Abstract
  118. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327. View Abstract
  119. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327. View Abstract
  120. Experience journals: using computers to share personal stories about illness and medical intervention. Stud Health Technol Inform. 1998; 52 Pt 2:1325-9. View Abstract
  121. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1997. View Abstract
  122. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996. View Abstract
  123. A Neural Network Approach to Modelling Personality Development. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996. View Abstract
  124. Book Review of Child and Adolescent Depression: Clinical and Research Perspectives. New England Journal of Medicine. 1996. View Abstract
  125. Transexuals: MCMI-II Severe Personality Disorder Incidence Depends on Setting and Sex. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1995. View Abstract
  126. A Computer Simulation of the Hypothalamic-Pituitary-Adrenal Axis. Presented at the American College of Neuropsychopharmacology Meeting. 1994. View Abstract
  127. A Computer Stimulation of the Hypothalamic-Pituitary-Adrenal Axis. Proceedings of the Annual Symposium on Computer Applications in Medical Care. 1994; 1010. View Abstract
  128. Book Review of The Kaspar Hauser Syndrome of "Psychosocial Dwarfism": Deficient Statural, Intellectual and Social Growth Induced by Child Abuse. New England Journal of Medicine. 1994; 331(15):1031. View Abstract
  129. A computer simulation of the hypothalamic-pituitary-adrenal axis. Proc Annu Symp Comput Appl Med Care. 1994; 1010. View Abstract
  130. Rates of Personality Disorders in Gender Dysphorics Using a Self Report Inventory, the MCMI-II. Presented at the XIII International Sympsium on Gender Dysphoria. 1993. View Abstract
  131. Using neural networks to model personality development. Med Hypotheses. 1993 Aug; 41(2):123-30. View Abstract
  132. Testing the psychogenic vomiting diagnosis. Four pediatric patients. Am J Dis Child. 1991 Aug; 145(8):913-6. View Abstract
  133. Testing the Psychogenic Vomitting Diagnosis: Four Pediatric Patients. American Journal of Diseases of Children. 1991; 148(8):913-916. View Abstract
  134. Postsynaptic localization of 5-HT1D receptor binding sites in human caudate. Exp Neurol. 1991 Jul; 113(1):28-30. View Abstract
  135. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry. 1990 Apr; 51 Suppl:5-12; discussion 13. View Abstract
  136. Aphrodiesiology: History, Folklore and Efficacy. In: The Pharmacology and Endocrinology of Sexual Function. Handbook of Sexology; series editors, Money, J., and Musaph, H. 1988; 6:499-515. View Abstract
  137. Reductions of Serotonergic Receptors in Alzheimer's Disease: An Autoradiographic Study. Abstract presented at the Meeting of the American Academy of Neurology, 1986. 1986. View Abstract

Contact Joseph Gonzalez-Heydrich

Print Profile